New drug combo aims to fight tough breast cancer

NCT ID NCT07045311

Recruiting now Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests two different drug combinations—JS207 plus 9MW2821 or JS207 plus albumin paclitaxel—as a first treatment for people with recurrent or metastatic triple-negative breast cancer. The study will enroll 80 participants to see if these combinations can shrink tumors and control the disease. Researchers will also monitor side effects and how long the benefits last.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS207 combined with 9MW2821 or albumin paclitaxel
What this could lead to: If successful, this could offer a new first-line treatment option for people with advanced triple-negative breast cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong: This is an early Phase 2 trial with only 80 participants, so results may not apply to everyone. The combination therapies may cause side effects, and there is no guarantee they will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Affiliated Hospital of Hebei University
RECRUITING

Baoding, Hebei, 071030, China
Affiliated Tumor Hospital of Xinjiang Medical University
RECRUITING

Ürümqi, Xinjiang Uygur Autonomous Region, 830000, China
Anhui Provincial Cancer Hospital
NOT_YET_RECRUITING

Hefei, Anhui, 230000, China
Ceneral Hosipital of Ningxia Medical University
NOT_YET_RECRUITING

Yinchuan, Ningxia, 750000, China
Guangdong women and children's hospital and health institute
NOT_YET_RECRUITING

Guangzhou, Guangdong, 511400, China
Harbin Medical University Affiliated Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150001, China
Harbin Medical University Affiliated Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150001, China
Henan Cancer Hospital
RECRUITING

Zhangzhou, Henan, 450003, China
Hubei Cancer Hospital
RECRUITING

Wuhan, Hubei, 430079, China
Jiangsu Cancer Hospital
RECRUITING

Nanjing, Jiangsu, 210009, China
Jiangsu Province Hospital
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210029, China
Jilin University First Hospital
RECRUITING

Changchun, Jilin, 130021, China
Liaoning Cancer Hospital&Institute
RECRUITING

Shenyang, Liaoning, 110801, China
Nanchang People'S Hospital
NOT_YET_RECRUITING

Nanchang, Jiangxi, 330000, China
Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100044, China
The Affiliated Hospital of Qingdao University
RECRUITING

Qingdao, Shandong, 266035, China
The Fifth Medical Center of PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100071, China
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xian, Shanxi, 710061, China
The First Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110002, China
The Second Affiliated Hospital Zhejiang University School of Medicine
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310000, China
The Second Hospital of Dalian Medical University
RECRUITING

Dalian, Liaoning, 116027, China
Xi'an International Medical Center Hospital
RECRUITING

Xian, Shanxi, 710100, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.